![Virtual Booth](https://www.pharmacompass.com/image/vb/vb-orange-btn.png)
![EuroAPI Header](https://www.pharmacompass.com/image/flap/euroapi-w34-desktop-headergif-72716.gif)
![EuroAPI Header](https://www.pharmacompass.com/image/flap/euroapi-w34-mob-headergif-95876.gif)
20
Hikal Limited Bangalore In, based in India, is a pharmaceutical company that stands out with its certifications from FDA, EDQM and WHO-GMP.
They are recognized for Partnering with Pharmaceutical, Life Sciences, Biotech & Specialty Chemicals Companies to deliver APIs, Intermediate & R&D Services.
One of their significant offerings is Flunarizine dihydrochloride, supported by a 'Valid' Certificate of Suitability (CEP) with the number CEP 2019-094 - Rev 02
This Chemical Type CEP, issued on October 27, 2023, remains in force until January 01, 1970, ensuring its reliability within the pharmaceutical industry.
Substance Number 1722 associated with this CEP further emphasizes